Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLUE-MI trial
jRCT1031240720Recruiting
- Sponsor
- Japan Society for the Promotion of Science
- Start
- Apr 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of canrenoic acid, carvedilol and resomelagon in myocardial infarction (MI) (2 arms), sponsored by Japan Society for the Promotion of Science. Primary endpoint: Relative change in NT-proBNP at 1 year. Started Apr 2025; status: recruiting.
02
Drugs
canrenoic acidcarvedilolresomelagon
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on jRCT1031240720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240720.